Organovo Holdings Inc logo

ONVO - Organovo Holdings Inc Share Price

$6.39 0.0  0.3%

Last Trade - 25/09/20

Micro Cap
Market Cap £32.7m
Enterprise Value £13.3m
Revenue £1.20m
Position in Universe 4883rd / 6417
Unlock ONVO Revenue
Relative Strength (%)
1m -23.9%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -65.6%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Mar 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
0.57 1.48 4.23 4.60 3.09 2.20 3.96 5.20 +30.9%
Balance Sheet
FINANCIAL BRIEF: : For the three months ended 30 June 2020, Organovo Holdings Inc revenues decreased from $668K to $0K. Net loss decreased 56% to $2.8M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Lower net loss reflects selling,general& admin value decrease of 15% to $1.9M (expense), Non-cash stock-based compensation decrease of 12% to $925K (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


ONVO Revenue Unlock ONVO Revenue

Net Income

ONVO Net Income Unlock ONVO Revenue

Normalised EPS

ONVO Normalised EPS Unlock ONVO Revenue

PE Ratio Range

ONVO PE Ratio Range Unlock ONVO Revenue

Dividend Yield Range

ONVO Dividend Yield Range Unlock ONVO Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
ONVO EPS Forecasts Unlock ONVO Revenue
Profile Summary

Organovo Holdings, Inc. is an early commercial-stage company focused on developing and commercializing functional human tissues. The Company focuses on the generation of three-dimensional (3D) human tissues, by utilizing its platform technology to create human tissue constructs in 3D. It is focused on development of products, including 3D human tissues used for the preclinical assessment of drug effects, including applications in predictive toxicology, absorption, distribution, metabolism, excretion (ADME), and drug metabolism and pharmacokinetics (DMPK); customized human tissues as living, dynamic models of human biology or disease, for use in drug discovery and development, and three-dimensional human tissues for clinical applications, such as blood vessels for bypass grafting, nerve grafts for nerve damage repair and functional tissue patches for the repair or replacement of damaged tissues and organs.

Last Annual March 31st, 2020
Last Interim June 30th, 2020
Incorporated January 27, 2012
Public Since August 2, 2013
No. of Shareholders: 88
No. of Employees: 6
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Capital Market
Shares in Issue 6,530,910
Free Float (0.0%)
Eligible for
ONVO Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for ONVO
Upcoming Events for ONVO
Frequently Asked Questions for Organovo Holdings Inc
What is the Organovo Holdings Inc share price?

As of 25/09/20, shares in Organovo Holdings Inc are trading at $6.39, giving the company a market capitalisation of £32.7m. This share price information is delayed by 15 minutes.

How has the Organovo Holdings Inc share price performed this year?

Shares in Organovo Holdings Inc are currently trading at $6.39 and the price has moved by 18.46% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Organovo Holdings Inc price has moved by 8.07% over the past year.

What are the analyst and broker recommendations for Organovo Holdings Inc?

Of the analysts with advisory recommendations for Organovo Holdings Inc, there are there are currently 0 "buy" , 2 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Organovo Holdings Inc is Hold. You can view the full broker recommendation list by unlocking its StockReport.

When will Organovo Holdings Inc next release its financial results?

Organovo Holdings Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-06-30
What is the Organovo Holdings Inc dividend yield?

Organovo Holdings Inc does not currently pay a dividend.

Does Organovo Holdings Inc pay a dividend?

Organovo Holdings Inc does not currently pay a dividend.

When does Organovo Holdings Inc next pay dividends?

Organovo Holdings Inc does not currently pay a dividend.

How do I buy Organovo Holdings Inc shares?

To buy shares in Organovo Holdings Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Organovo Holdings Inc?

Shares in Organovo Holdings Inc are currently trading at $6.39, giving the company a market capitalisation of £32.7m.

Where are Organovo Holdings Inc shares listed? Where are Organovo Holdings Inc shares listed?

Here are the trading details for Organovo Holdings Inc:

Country of listing: United States
Exchange: NAQ
Ticker Symbol: ONVO
What kind of share is Organovo Holdings Inc?

Based on an overall assessment of its quality, value and momentum, Organovo Holdings Inc is currently classified as a Falling Star. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Organovo Holdings Inc share price forecast 2020?

Shares in Organovo Holdings Inc are currently priced at $6.39. At that level they are trading at 53.05% premium to the analyst consensus target price of 0.00.

Analysts covering Organovo Holdings Inc currently have a consensus Earnings Per Share (EPS) forecast of -0.21 for the next financial year.

How can I tell whether the Organovo Holdings Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Organovo Holdings Inc. Over the past six months, the relative strength of its shares against the market has been -10.71%. At the current price of $6.39, shares in Organovo Holdings Inc are trading at -30.97% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Organovo Holdings Inc PE Ratio?

We were not able to find PE ratio data for Organovo Holdings Inc.

Who are the key directors of Organovo Holdings Inc?

Organovo Holdings Inc's management team is headed by:

Keith Murphy - CHM
Adam Stern - IND
Paul Gallant - GMG
Steven Hughes - OTH
Douglas Cohen - IND
David Gobel - IND
Alison Milhous - IND
Chris Heberlig - PRE
Jeffrey Miner - CSO
Thomas Jurgensen - GCN
Who are the major shareholders of Organovo Holdings Inc?

Here are the top five shareholders of Organovo Holdings Inc based on the size of their shareholding:

ARK Investment Management LLC Investment Advisor
Percentage owned: 21.03% (1.37m shares)
ARK Innovation ETF Mutual Fund
Percentage owned: 13.06% (853k shares)
Nikko Asset Management Americas, Inc. Investment Advisor/Hedge Fund
Percentage owned: 9.81% (12.8m shares)
Nikko Asset Management Co., Ltd. Investment Advisor/Hedge Fund
Percentage owned: 7.5% (490k shares)
ARK Genomic Revolution ETF Mutual Fund
Percentage owned: 5.92% (387k shares)
Similar to ONVO
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.